Stockscreener 앱 받기
80.82
2.12%
1.68
시간 외 거래:
80.99
0.17
+0.21%
전일 마감가:
$79.14
열려 있는:
$79.19
하루 거래량:
1.47M
Relative Volume:
0.62
시가총액:
$13.09B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-26.59
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
-1.05%
1개월 성능:
+11.22%
6개월 성능:
+126.90%
1년 성능:
+118.37%
1일 변동 폭
$78.50
$80.92
1주일 범위
$77.79
$82.86
52주 변동 폭
$23.95
$83.61
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
80.82 | 12.82B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionFed Meeting & Weekly High Return Stock Forecasts - Newser
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersMarket Activity Summary & Community Consensus Stock Picks - Newser
Ionis Pharmaceuticals Earnings Notes - Trefis
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD - Investing.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on growth outlook - Investing.com Canada
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug By Investing.com - Investing.com Canada
Granite Investment Partners LLC Trims Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Why Ionis Pharmaceuticals Inc. (ISI) stock could break out in 2025July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
How robust is Ionis Pharmaceuticals Inc. (ISI) stock financial position - Newser
What hedge fund activity signals for Ionis Pharmaceuticals Inc. stock2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week HighStill a Buy? - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Desi - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS) - GuruFocus
Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation - marketscreener.com
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug - Investing.com
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire
How Ionis Pharmaceuticals Inc. (ISI) stock performs during market turbulenceEntry Point & Low Risk Entry Point Tips - Newser
FDA grants breakthrough therapy status to Ionis’ olezarsen for severe HTG - Investing.com Australia
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen - Sahm
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen - Yahoo Finance
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? - Yahoo Finance
Ionis receives U.S. FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridemia - marketscreener.com
Ionis Says Olezarsen Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia - marketscreener.com
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuti - GuruFocus
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - The Manila Times
Ionis Pharmaceuticals shares up 3.5% premarket after co receives FDA breakthrough therapy designation for olezarsen for SHTG - marketscreener.com
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) - Business Wire
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):